

# Becker Muscular Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/B44059D647E5EN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: B44059D647E5EN

## Abstracts

The 7 major Becker muscular dystrophy markets reached a value of US\$ 848.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 1,283.5 Million by 2034, exhibiting a growth rate (CAGR) of 3.84% during 2024-2034.

The Becker muscular dystrophy market has been comprehensively analyzed in IMARC's new report titled "Becker Muscular Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Becker muscular dystrophy (BMD) refers to a genetic condition characterized by progressive muscle wasting and weakness. The symptoms of the disease usually appear in late childhood or adolescence, although they can manifest at any age. The main indication associated with this illness is rapid and gradual muscle weakness that affects the hips, pelvic area, thighs, arms, legs, and heart. Various other symptoms commonly seen in individuals suffering from the ailment include difficulty walking, a waddling gait, frequent falls, calf muscle enlargement, cramps, etc. As the disease progresses, patients may further develop contractures (joint stiffness) and respiratory problems. The diagnosis of BMD typically involves a combination of clinical evaluation, family history assessment, and a physical examination. A healthcare provider may also perform genetic testing via DNA sequencing or multiplex ligation-dependent probe amplification to identify mutations or alterations in the genome that might be contributing to the underlying disorder. In some cases, a biopsy will be recommended to examine muscle tissue under a microscope. This helps to reveal specific changes in the muscle fibers that are characteristic of the ailment.

The increasing cases of mutations in the dystrophin gene, which result in the disruption of vital structural and signaling functions within muscle cells, are primarily driving the

Becker muscular dystrophy market. In addition to this, the inflating utilization of corticosteroids, such as prednisone and deflazacort, to slow down muscle degeneration and improve strength in patients is also creating a positive outlook for the market. Moreover, the widespread adoption of several assistive devices, like braces, splints, orthotics, etc., since they provide support, maintain joint alignment, and prevent contractures in individuals suffering from BMD, is further bolstering the market growth. Apart from this, the rising application of physical and occupational therapies that aim to enhance functional abilities and promote independence through exercises and stretches is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which involves delivering functional copies of the defective gene directly into the affected cells to restore the production of a full-length dystrophin protein, is expected to drive the Becker muscular dystrophy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Becker muscular dystrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Becker muscular dystrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Becker muscular dystrophy market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the Becker muscular dystrophy market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the Becker muscular dystrophy market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Becker muscular dystrophy marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the Becker muscular dystrophy market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Becker muscular dystrophy market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Becker muscular dystrophy market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of Becker muscular dystrophy across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of Becker muscular dystrophy by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of Becker muscular dystrophy by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with Becker muscular dystrophy across the seven major markets?

What is the size of the Becker muscular dystrophy patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Becker muscular dystrophy?

What will be the growth rate of patients across the seven major markets?

### Becker Muscular Dystrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Becker muscular dystrophy drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Becker muscular dystrophy market?

What are the key regulatory events related to the Becker muscular dystrophy market?

What is the structure of clinical trial landscape by status related to the Becker muscular dystrophy market?

What is the structure of clinical trial landscape by phase related to the Becker muscular dystrophy market?

What is the structure of clinical trial landscape by route of administration related to the Becker muscular dystrophy market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 BECKER MUSCULAR DYSTROPHY - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 BECKER MUSCULAR DYSTROPHY - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 BECKER MUSCULAR DYSTROPHY - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (?2018-2034?)
- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 BECKER MUSCULAR DYSTROPHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 BECKER MUSCULAR DYSTROPHY - UNMET NEEDS**

## **10 BECKER MUSCULAR DYSTROPHY - KEY ENDPOINTS OF TREATMENT**

## **11 BECKER MUSCULAR DYSTROPHY - MARKETED PRODUCTS**

- 11.1 List of Becker Muscular Dystrophy Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 BECKER MUSCULAR DYSTROPHY - PIPELINE DRUGS**

### 12.1 List of Becker Muscular Dystrophy Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 EDG-5506 - Edgewise Therapeutics

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

#### 12.1.2 ITF2357 - Italfarmaco

##### 12.1.2.1 Drug Overview

##### 12.1.2.2 Mechanism of Action

##### 12.1.2.3 Clinical Trial Results

##### 12.1.2.4 Safety and Efficacy

##### 12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. BECKER MUSCULAR DYSTROPHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. BECKER MUSCULAR DYSTROPHY – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 BECKER MUSCULAR DYSTROPHY - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Becker Muscular Dystrophy - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Becker Muscular Dystrophy - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Becker Muscular Dystrophy - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Becker Muscular Dystrophy - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

#### 15.3.3 Becker Muscular Dystrophy - Access and Reimbursement Overview

### 15.4 Market Scenario - Germany

#### 15.4.1 Becker Muscular Dystrophy - Market Size

##### 15.4.1.1 Market Size (2018-2023)

##### 15.4.1.2 Market Forecast (2024-2034)

#### 15.4.2 Becker Muscular Dystrophy - Market Size by Therapies

##### 15.4.2.1 Market Size by Therapies (2018-2023)

##### 15.4.2.2 Market Forecast by Therapies (2024-2034)

#### 15.4.3 Becker Muscular Dystrophy - Access and Reimbursement Overview

### 15.5 Market Scenario - France

#### 15.5.1 Becker Muscular Dystrophy - Market Size

##### 15.5.1.1 Market Size (2018-2023)

##### 15.5.1.2 Market Forecast (2024-2034)

#### 15.5.2 Becker Muscular Dystrophy - Market Size by Therapies

##### 15.5.2.1 Market Size by Therapies (2018-2023)

##### 15.5.2.2 Market Forecast by Therapies (2024-2034)

#### 15.5.3 Becker Muscular Dystrophy - Access and Reimbursement Overview

### 15.6 Market Scenario - United Kingdom

#### 15.6.1 Becker Muscular Dystrophy - Market Size

##### 15.6.1.1 Market Size (2018-2023)

##### 15.6.1.2 Market Forecast (2024-2034)

#### 15.6.2 Becker Muscular Dystrophy - Market Size by Therapies

##### 15.6.2.1 Market Size by Therapies (2018-2023)

##### 15.6.2.2 Market Forecast by Therapies (2024-2034)

#### 15.6.3 Becker Muscular Dystrophy - Access and Reimbursement Overview

### 15.7 Market Scenario - Italy

#### 15.7.1 Becker Muscular Dystrophy - Market Size

##### 15.7.1.1 Market Size (2018-2023)

##### 15.7.1.2 Market Forecast (2024-2034)

#### 15.7.2 Becker Muscular Dystrophy - Market Size by Therapies

##### 15.7.2.1 Market Size by Therapies (2018-2023)

##### 15.7.2.2 Market Forecast by Therapies (2024-2034)

- 15.7.3 Becker Muscular Dystrophy - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Becker Muscular Dystrophy - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Becker Muscular Dystrophy - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Becker Muscular Dystrophy - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Becker Muscular Dystrophy - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Becker Muscular Dystrophy - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Becker Muscular Dystrophy - Access and Reimbursement Overview

## **16 BECKER MUSCULAR DYSTROPHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 BECKER MUSCULAR DYSTROPHY MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 BECKER MUSCULAR DYSTROPHY MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Becker Muscular Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/B44059D647E5EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B44059D647E5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

